

# 31 January 2020

#### **NSX and OTCQX Announcement**

## **Issue of Shares**

Beroni Group Limited (NSX:BTG, OTCQX:BNIGF) ("Beroni" or the "Company") is pleased to announce that it has issued 200,000 shares at \$1.00 to an existing shareholder raising \$200,000 cash.

## Notice given under section 708A(5) of the Corporations Act 2001 (Cth)

This notice is given by the Company under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) in relation to an issue of 200,000 fully paid shares by the Company without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, the Company has complied with:

- 1. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
- 2. section 674 of the Corporations Act.

There is no excluded information as at the date of this notice, for the purposes of Section 708A (7) and (8) of the Corporations Act.

-End-

For further information please contact:

Mr Jacky Zhang Mr Peter Wong

Executive Chairman Executive Director and CFO

Tel: +86 1851 6931 911 Tel: +61 423 727 580

#### About Beroni Group Limited (NSX:BTG) (OTCQX:BNIGF)

Beroni Group (NSX: BTG; OTCQX: BNIGF) is an international biopharmaceutical enterprise focused on the research, development, innovation and commercialization of biopharmaceutical therapies and products. Beroni's diversified core businesses are comprised of the company's Innovation Pathways, which include cell therapies and anti-cancer (oncology) therapies; and its Commercial Pathways, which include infectious disease diagnostics & detection products, and an e-commerce sales platform for healthcare and pharmaceutical products.